CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.92 +0.02 (+2.22%)
At close: Oct 2, 2026 · 4:00 PM EDT

CytoMed Therapeutics (GDTC) Other Accumulated Expenses (2022)

Updated

CytoMed Therapeutics' Other Accumulated Expenses came in at $300,000 for Q4 2022.

Analysis

CytoMed Therapeutics (GDTC) Other Accumulated Expenses (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 CytoMed Therapeutics 10.88 Mn -200,496.58 -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 300,000.00
API Access

CytoMed Therapeutics Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=GDTC&period=max&api_key=YOUR_API_KEY